Literature DB >> 14633608

Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection.

Thomas W Geisbert1, Lisa E Hensley, Tom Larsen, Howard A Young, Douglas S Reed, Joan B Geisbert, Dana P Scott, Elliott Kagan, Peter B Jahrling, Kelly J Davis.   

Abstract

Ebola virus (EBOV) infection causes a severe and fatal hemorrhagic disease that in many ways appears to be similar in humans and nonhuman primates; however, little is known about the development of EBOV hemorrhagic fever. In the present study, 21 cynomolgus monkeys were experimentally infected with EBOV and examined sequentially over a 6-day period to investigate the pathological events of EBOV infection that lead to death. Importantly, dendritic cells in lymphoid tissues were identified as early and sustained targets of EBOV, implicating their important role in the immunosuppression characteristic of EBOV infections. Bystander lymphocyte apoptosis, previously described in end-stage tissues, occurred early in the disease-course in intravascular and extravascular locations. Of note, apoptosis and loss of NK cells was a prominent finding, suggesting the importance of innate immunity in determining the fate of the host. Analysis of peripheral blood mononuclear cell gene expression showed temporal increases in tumor necrosis factor-related apoptosis-inducing ligand and Fas transcripts, revealing a possible mechanism for the observed bystander apoptosis, while up-regulation of NAIP and cIAP2 mRNA suggest that EBOV has evolved additional mechanisms to resist host defenses by inducing protective transcripts in cells that it infects. The sequence of pathogenetic events identified in this study should provide new targets for rational prophylactic and chemotherapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633608      PMCID: PMC1892369          DOI: 10.1016/S0002-9440(10)63591-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  78 in total

1.  Effect of clarithromycin and azithromycin on production of cytokines by human monocytes.

Authors:  A A Khan; T R Slifer; F G Araujo; J S Remington
Journal:  Int J Antimicrob Agents       Date:  1999-02       Impact factor: 5.283

2.  Measles virus induces functional TRAIL production by human dendritic cells.

Authors:  P O Vidalain; O Azocar; B Lamouille; A Astier; C Rabourdin-Combe; C Servet-Delprat
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  [Attempts to develop a vaccine against Ebola fever].

Authors:  A A Chupurnov; I V Chernukhin; V A Ternovoĭ; N M Kudoiarova; N M Makhova; M Sh Azaev; M P Smolina
Journal:  Vopr Virusol       Date:  1995 Nov-Dec

4.  Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients.

Authors:  S Baize; E M Leroy; M C Georges-Courbot; M Capron; J Lansoud-Soukate; P Debré; S P Fisher-Hoch; J B McCormick; A J Georges
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

5.  Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis.

Authors:  E Ryabchikova; L Kolesnikova; M Smolina; V Tkachev; L Pereboeva; S Baranova; A Grazhdantseva; Y Rassadkin
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

6.  Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections.

Authors:  P B Jahrling; T W Geisbert; J B Geisbert; J R Swearengen; M Bray; N K Jaax; J W Huggins; J W LeDuc; C J Peters
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

7.  [Development and study of the properties of immunoglobulin against Ebola fever].

Authors:  I V Borisevich; V V Mikhaĭlov; V P Krasnianskiĭ; V N Gradoboev; E V Lebedinskaia; N V Potryvaeva; G D Timan'kova
Journal:  Vopr Virusol       Date:  1995 Nov-Dec

8.  Maturation, activation, and protection of dendritic cells induced by double-stranded RNA.

Authors:  M Cella; M Salio; Y Sakakibara; H Langen; I Julkunen; A Lanzavecchia
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

9.  Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs.

Authors:  N Kayagaki; N Yamaguchi; M Nakayama; H Eto; K Okumura; H Yagita
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

10.  Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL.

Authors:  T S Griffith; S R Wiley; M Z Kubin; L M Sedger; C R Maliszewski; N A Fanger
Journal:  J Exp Med       Date:  1999-04-19       Impact factor: 14.307

View more
  273 in total

1.  Inhibition of heat-shock protein 90 reduces Ebola virus replication.

Authors:  Darci R Smith; Sarah McCarthy; Andrew Chrovian; Gene Olinger; Andrea Stossel; Thomas W Geisbert; Lisa E Hensley; John H Connor
Journal:  Antiviral Res       Date:  2010-05-07       Impact factor: 5.970

2.  Ebola virus transmission in guinea pigs.

Authors:  Gary Wong; Xiangguo Qiu; Jason S Richardson; Todd Cutts; Brad Collignon; Jason Gren; Jenna Aviles; Carissa Embury-Hyatt; Gary P Kobinger
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

3.  DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus.

Authors:  Andrea Marzi; Thomas Gramberg; Graham Simmons; Peggy Möller; Andrew J Rennekamp; Mandy Krumbiegel; Martina Geier; Jutta Eisemann; Nadine Turza; Bertrand Saunier; Alexander Steinkasserer; Stephan Becker; Paul Bates; Heike Hofmann; Stefan Pöhlmann
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

4.  Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus.

Authors:  Hideki Ebihara; Barry Rockx; Andrea Marzi; Friederike Feldmann; Elaine Haddock; Douglas Brining; Rachel A LaCasse; Don Gardner; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

5.  Ebola virus failure to stimulate plasmacytoid dendritic cell interferon responses correlates with impaired cellular entry.

Authors:  Lawrence W Leung; Osvaldo Martinez; Olivier Reynard; Viktor E Volchkov; Christopher F Basler
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

6.  Humanized Mice--A Neoteric Animal Disease Model for Ebola Virus?

Authors:  Joseph Prescott; Heinz Feldmann
Journal:  J Infect Dis       Date:  2015-11-17       Impact factor: 5.226

7.  Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies.

Authors:  Philipp A Ilinykh; Kai Huang; Rodrigo I Santos; Pavlo Gilchuk; Bronwyn M Gunn; Marcus M Karim; Jenny Liang; Mallorie E Fouch; Edgar Davidson; Diptiben V Parekh; James B Kimble; Colette A Pietzsch; Michelle Meyer; Natalia A Kuzmina; Larry Zeitlin; Erica Ollmann Saphire; Galit Alter; James E Crowe; Alexander Bukreyev
Journal:  Cell Host Microbe       Date:  2020-04-21       Impact factor: 21.023

8.  Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells.

Authors:  Joshua C Johnson; Osvaldo Martinez; Anna N Honko; Lisa E Hensley; Gene G Olinger; Christopher F Basler
Journal:  Antiviral Res       Date:  2014-05-09       Impact factor: 5.970

Review 9.  Epidemiology and Management of the 2013-16 West African Ebola Outbreak.

Authors:  M L Boisen; J N Hartnett; A Goba; M A Vandi; D S Grant; J S Schieffelin; R F Garry; L M Branco
Journal:  Annu Rev Virol       Date:  2016-08-15       Impact factor: 10.431

10.  Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever.

Authors:  Lauren M Smith; Lisa E Hensley; Thomas W Geisbert; Joshua Johnson; Andrea Stossel; Anna Honko; Judy Y Yen; Joan Geisbert; Jason Paragas; Elizabeth Fritz; Gene Olinger; Howard A Young; Kathleen H Rubins; Christopher L Karp
Journal:  J Infect Dis       Date:  2012-12-18       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.